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Introduction
 
As Type 2 diabetes advances, progressive islet B-cell dysfunc-
tion leads to a deterioration in glycaemic control and most
people eventually require insulin treatment, often at high doses
because of insulin insensitivity [1]. One approach to optimizing
the effectiveness of insulin is to continue oral glucose-lowering
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Abstract
 
Aims
 
To compare the efficacy and safety of either continuing or discontinuing
rosiglitazone 
 
+
 
 metformin fixed-dose combination when starting insulin therapy
in people with Type 2 diabetes inadequately controlled on oral therapy.
 
Methods
 
In this 24-week double-blind study, 324 individuals with Type 2 diabetes
inadequately controlled on maximum dose rosiglitazone 
 
+
 
 metformin therapy
were randomly assigned to twice-daily premix insulin therapy (target pre-breakfast
and pre-evening meal glucose 
 
≤
 
 6.5 mmol/l) in addition to either rosiglitazone
 
+
 
 metformin (8/2000 mg) or placebo.
 
Results
 
Insulin dose at week 24 was significantly lower with rosiglitazone 
 
+
 
 metformin
(33.5 
 
±
 
 1.5 U/day, mean 
 
±
 
 
 
SE
 
) compared with placebo [59.0 
 
±
 
 3.0 U/day; model-
adjusted difference 
 
−
 
26.6 (95% CI 
 
−
 
37.7, 
 
−
 
15,5) U/day, 
 
P
 
 
 
<
 
 0.001]. Despite this, there
was greater improvement in glycaemic control [HbA
 
1c
 
 rosiglitazone 
 
+
 
 metformin
vs. placebo 6.8 
 
±
 
 0.1 vs. 7.5 
 
±
 
 0.1%; difference 
 
−
 
0.7 (
 
−
 
0.8, 
 
−
 
0.5)%, 
 
P
 
 
 
<
 
 0.001] and
more individuals achieved glycaemic targets (HbA
 
1c
 
 
 
<
 
 7.0% 70 vs. 34%, 
 
P
 
 
 
<
 
 0.001).
The proportion of individuals reporting at least one hypoglycaemic event during
the last 12  weeks of treatment was similar in the two groups (rosiglitazone
 
+
 
 metformin vs. placebo 25 vs. 27%). People receiving rosiglitazone 
 
+
 
 metformin
in addition to insulin reported greater treatment satisfaction than those receiving
insulin alone. Both treatment regimens were well tolerated but more participants
had oedema [12 (7%) vs. 4 (3%)] and there was more weight gain [3.7 vs. 2.6 kg;
difference 1.1 (0.2, 2.1) kg, 
 
P
 
 
 
=
 
 0.02] with rosiglitazone 
 
+
 
 metformin.
 
Conclusions
 
Addition of insulin to rosiglitazone 
 
+
 
 metformin enabled more
people to reach glycaemic targets with less insulin, and was generally well tolerated.
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drugs (OGLDs) when starting insulin, rather than changing to
insulin alone. Studies suggest that this reduces the insulin dose
requirement by approximately 20% in combination with one
oral agent, and approximately 40% with both a sulphonylurea
and metformin, while achieving similar glycaemic control [2,3].
In a 1-year study of previously insulin-naive people, combi-
nation metformin and bedtime insulin gave greater improvement
in glycaemic control with less hypoglycaemia than bedtime
insulin with sulphonylurea, sulphonylurea plus metformin, or
morning insulin [4]. Body weight was unchanged with insulin
and metformin, but increased in the other groups. People on
maximum-tolerated doses of OGLDs who continued met-
formin with insulin used less insulin, had less weight gain, and
achieved better glycaemic control compared with insulin plus
placebo [5,6]. Hence, guidelines recommend continuing
metformin (and other OGLDs) when starting insulin [7,8].
People with poor glucose control on metformin alone can benefit
from addition of a thiazolidinedione [9,10] and, in studies with
rosiglitazone added to metformin, homeostasis model assessment
(HOMA) estimates of insulin sensitivity and islet B-cell dysfunction
also improved [11,12]. This suggests the actions of the two drugs
are complementary [13–16]. In addition, because gastrointestinal
side-effects with metformin are dose related [17], a lower incidence
can be achieved by combination with rosiglitazone through
reduction of metformin dose [12]. There is also reduced weight
gain compared with thiazolidinedione monotherapy [10,18].
Adding rosiglitazone to insulin therapy was found to reduce
glycated haemoglobin (HbA
 
1c
 
) by 1.2% (
 
P
 
 
 
<
 
 0.001), along with
a 12% reduction of insulin dosage, but with increased oedema
and weight gain [19,20]. As the use of exogenous insulin is also
associated with fluid retention, the tolerability of rosiglitazone
and insulin in combination warrants further investigation.
While that study evaluated the addition of rosiglitazone to
insulin [19], the effect of adding insulin to rosiglitazone, which
would be the commoner clinical scenario, has not been studied.
Many individuals are treated with a combination of OGLDs before
insulin is started; therefore, the continuation or discontinuation
of combination therapy warrants investigation [8]. Theoretically,
individuals taking optimized doses of rosiglitazone and met-
formin combination may require less insulin to achieve target
glycaemic control compared with insulin alone or insulin plus
either oral agent. Additionally, weight gain might be controlled
by the metformin component, but hypoglycaemia might increase
or decrease. The purpose of the current study was therefore to
compare the efficacy and safety of either continuing or discon-
tinuing rosiglitazone 
 
+
 
 metformin fixed-dose combination (rosi
 
+ 
 
met) when starting insulin in people with Type 2 diabetes
inadequately controlled on maximal dose rosi 
 
+ 
 
met.
 
Research design and methods
 
Study population
 
Men and women aged 18–70 years with Type 2 diabetes
(defined according to World Health Organization criteria [21])
were considered for this 24-week, multicentre, randomized, double-
blind, parallel group study. Participants were recruited from 73
centres in five European countries. The study was conducted in
accordance with Good Clinical Practice guidelines and the 1996
version of the Declaration of Helsinki. Written informed consent
was obtained from all participants. The study protocol and
informed consent were approved by an ethics committee or
institutional review board according to local requirements.
Participants had body mass index 
 
≥
 
 25.0 kg/m
 
2
 
, HbA
 
1c
 
 7.1–
10.0% at screening (visit 0; week 
 
−
 
10), and were receiving 
 
≥
 
 1500 mg
metformin alone or in combination with other OGLDs at constant
doses for 
 
≥
 
 8 weeks prior to entry. Exclusion criteria included use
of insulin in the 3 months before screening; a history of acidosis;
ongoing oedema requiring pharmacological treatment; unstable or
severe angina or any class of congestive heart failure; or myocardial
infarction, percutaneous transluminal coronary angioplasty,
coronary artery bypass grafting or stroke within 3 months. Other
exclusion criteria included blood pressure 
 
>
 
 160/90 mmHg
while on anti-hypertensive treatment, anaemia (Hb 
 
<
 
 11.0 g/dl
in men and 
 
<
 
 10.0 g/dl in women), renal dysfunction (serum
creatinine 
 
>
 
 135 
 
µ
 
mol/l in men and 
 
>
 
 110 
 
µ
 
mol/l in women),
hepatic disease, and fasting serum C-peptide 
 
≤
 
 0.50 nmol/l.
 
Study design
 
Eligible participants were enrolled into an 8-week, single-blind,
run-in phase. During this time, prior OGLD treatment was
changed to rosi 
 
+ 
 
met 8 
 
+ 
 
2000 mg (4 
 
+ 
 
1000 mg twice daily). At
the end of the run-in period, eligible participants with a clinic
fasting plasma glucose (FPG) 
 
≥
 
 7.0 mmol/l 2 weeks previously
(
 
n
 
 
 
=
 
 324) were randomized to either rosi 
 
+ 
 
met 8 
 
+ 
 
2000 mg plus
insulin (
 
n
 
 
 
=
 
  163) or matched placebo plus insulin (
 
n
 
 
 
=
 
 161)
double-blind for 24  weeks. Randomization was remote and
concealed from centres, was gender stratified, and used a block
randomization method. The combination of a thiazolidinedi-
one with insulin remains investigational at the time of writing
and is not a licensed indication in some countries.
The safety population included all randomized individuals
who received at least one dose of double-blind study medica-
tion (rosi 
 
+ 
 
met 
 
n
 
 
 
=
 
 162; placebo 
 
n
 
 
 
=
 
 160), and the intent-to-treat
(ITT) population included all those who had at least one valid
on-therapy observation for an efficacy variable (rosi 
 
+ 
 
met
 
n
 
 
 
=
 
 161; placebo 
 
n
 
 
 
=
 
 158). The baseline clinical characteristics
of the groups were well matched (Table 1).
All participants were started on 24 U/day of locally sourced
premixed insulin (12 U before breakfast and 12 U before the
evening meal), the ‘baseline’ dose. Following training provided
by the investigator or a trained designee, participants were
asked to make self-monitored blood glucose (SMBG) measure-
ments using a blood glucose meter calibrated to whole blood,
and to record the results on diary cards. On beginning insulin
they were requested to test four times daily to drive insulin dose
adjustment according to protocol-specific algorithms, every 3–
5 days until a target pre-breakfast and pre-evening meal blood
glucose level of 
 
≤
 
 6.5 mmol/l was achieved. After the target was
reached, tests were requested to be carried out twice daily three
times weekly, but four times daily for 3–5 days prior to the next
clinic visit. If an SMBG level 
 
≤
 
 4.0 mmol/l was recorded that could
not be explained, the insulin dose was to be decreased by 10%.
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Participants were educated by a qualified nutrition professional
on following a diet designed to maintain their current weight.
Individuals were discontinued from the study (see numbers below)
if they experienced unacceptable hypoglycaemia, exacerbation
of ongoing oedema during the run-in, new oedema prior to rando-
mization or lack of efficacy defined by increased FPG or symptomatic
hyperglycaemia deemed by the investigator to be a safety risk.
 
Study assessments
 
Eleven study visits were scheduled from screening (week 
 
−
 
10)
to study end, at which fasting blood samples were taken (before
the morning insulin injection). Assays were performed at a cen-
tral laboratory (Quest Diagnostics, Heston, UK) using standard
assays. The primary efficacy end point was the change in HbA
 
1c
 
from baseline (week 0) to week 24. HbA
 
1c
 
 was measured by
high-performance liquid chromatography (HPLC) using a Dia-
betes Control and Complications Trial (DCCT)-harmonized
assay. Secondary end points included change in office-sampled
laboratory-measured FPG from baseline to week 24, the pro-
portion of participants who achieved HbA
 
1c
 
 and FPG targets,
daily insulin dose, and hypoglycaemic events during the last
12  weeks of the study (in the expectation that insulin dose
would be relatively stable by week 12). Participants were
instructed to record symptomatic hypoglycaemia on diary cards
with an SMBG result. Investigators were asked to confirm hypo-
glycaemia by careful history and the SMBG result. Compliance
with insulin-dose algorithms was assessed at week 24 based on
diary card records. This suggested compliance ‘all of the time’
or ‘most of the time’ by 124 (77%) participants in the rosi 
 
+ 
 
met
group and by 110 (69%) participants in the placebo group.
Changes in islet B-cell dysfunction were assessed through changes
in proinsulin, C-peptide and proinsulin:C-peptide ratio. Health
outcome variables were measured using Diabetes Treatment
Satisfaction Questionnaire status (DTSQs) and DTSQ change
(DTSQc) total scores. These are self-administered and validated
instruments [22]. Safety variables included adverse events (AEs)
recorded by the investigator and assessed as mild, moderate or severe.
 
Statistical analysis
 
The differences between treatment groups for mean change in
HbA
 
1c
 
, FPG and DTSQs were assessed by an 
 
ANCOVA
 
 model
with terms for treatment, country, gender and baseline
measurement. DTSQc was analysed similarly but with no
baseline measurement. Analysis of treatment difference for
total daily insulin dose was assessed using a repeated-
measures analysis model with terms for treatment, country,
gender, time (visit) and treatment-by-time (visit). C-peptide,
proinsulin and proinsulin:C-peptide ratio data were analysed
non-parametrically as change from baseline because of
non-normal data distribution. Comparisons between treat-
ment  groups in the proportion of participants achieving
HbA
 
1c
 
 
 
≤
 
 6.5% and 
 
<
 
 7.0%, and FPG 
 
≤
 
 6.5 mmol/l were
assessed using a logistic regression model with terms for
treatment, gender and baseline measurement, with treatment
comparison estimated as odds ratios.
Treatment difference for the total number of hypoglycaemic
events in the last 12 weeks of the study was assessed based on
Poisson regression model analysis with terms of treatment, gender
and baseline measurement, accounting for duration of therapy.
Safety measures were summarized by treatment group.
 
Results
 
Study population
 
Twenty-seven participants (8%) from the safety population
withdrew during the double-blind phase. The primary reasons
were participant decision [6 (4%) in each group] and AEs
[rosi 
 
+ 
 
met 4  (2%); placebo 4 (3%)]. Withdrawals of note included
in the rosi 
 
+ 
 
met group two as a result of oedema and one as a
result of abdominal discomfort, and in the placebo group one
as a result of weight gain. One person on rosi 
 
+ 
 
met and two on
placebo were withdrawn by investigators for lack of efficacy,
and three on rosi 
 
+ 
 
met and one on placebo for protocol violation.
 
Insulin doses
 
Daily insulin dose in the two groups was diverging by week 2
(Fig. 1) and was significantly lower in the rosi 
 
+ 
 
met group at
every visit from week 2, with treatment differences increasing
with time. Most dose adjustment occurred in the first 4 weeks
in both groups (Fig.  1). At week  24, there was a model-
Rosiglitazone + 
metformin and insulin
Placebo 
and insulin
Safety population (n) 162 160
Age (years) 57.2 ± 8.6 56.9 ± 9.1
Sex [M/F, n (%)] 84/78 (52/48) 85/75 (53/47)
Race [white/other, n (%)] 158/4 (98/2) 158/2 (99/1)
Body weight (kg) 88.9 ± 15.3 92.1 ± 16.8
Body mass index (kg/m2) 31.8 ± 4.7 32.5 ± 5.2
Duration from diagnosis (years) 9.2 ± 6.1 8.5 ± 6.0
Prior glucose-lowering drug use 
[one/two daily at entry, n (%)]
33/129 (20/80) 31/129 (19/81)
Mean ± SD, or n (%).
Baseline blood glucose control data are given in Table 2.
Table 1 Clinical characteristics at 
randomization of the people with Type 2 
diabetes studied
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adjusted mean difference of 
 
−
 
26.6 (95% CI 
 
−
 
37.7, 
 
−
 
15.5) U/
day, 
 
P
 
 
 
<
 
 0.001 (Table 2).
 
Glycaemic control
 
The group continuing rosi 
 
+ 
 
met achieved significantly greater
improvement in HbA
 
1c
 
 between baseline and week 24 com-
pared with the placebo group [difference 
 
−
 
0.7 (
 
−0.8, −0.5)%,
P < 0.001; Fig. 1, Table 2]. A significantly greater proportion
of people receiving rosi + met achieved treatment targets of
HbA1c ≤ 6.5 and < 7.0% compared with those in the placebo
group (P < 0.001; Table 2); 46% in the rosi + met group achieved
the stricter target.
The fall in clinic FPG was early and rapid in the group
continuing rosi + met (Fig. 1). At week 24, there was a greater
reduction in clinic FPG in the rosi + met group compared with
the placebo group, with a difference between the two groups
of −1.4 (−1.9, −0.9) mmol/l, P < 0.001 (Table 2). A significantly
greater proportion of individuals who received rosi + met achieved
the clinic FPG target ≤ 6.5 mmol/l (P = 0.001; Table 2).
SMBG data were collected to assist in insulin dose titration
and were not compared statistically. In the rosi + met group,
mean daily SMBG measurement fell from 10.0 ± 0.2 mmol/l
at baseline to 6.8 ± 0.1 mmol/l at week 24. The mean SMBG
reduced from 10.0 ± 0.2 mmol/l to 8.2 ± 0.2 mmol/l in the
placebo group (Table 2).
Hypoglycaemia and body weight
During the last 12 weeks of the study, the number of partici-
pants who reported biochemically confirmed hypoglycaemia
with and without symptoms was similar between groups:
rosi + met vs. placebo 33 vs. 32 and 9 vs. 13, respectively. The
number of participants who reported symptomatic hypogly-
caemia which was not biochemically confirmed was also similar
with rosi + met and placebo (5 vs. 5 individuals). The number of
participants reporting at least one hypoglycaemic event of any
kind during the last 12 weeks of the study was very similar in
the two groups: 40 (25%) in the rosi + met group and 43 (27%)
in the placebo group. Although the total number of reported
events was higher with rosi + met (166 vs. 130 events), the event
rate was not statistically significantly different (Table 2). No
severe events or events leading to withdrawal from study
medication occurred.
Body weight increased in both groups, with a significantly
greater increase in the rosi + met group [mean difference 1.1
(0.2, 2.1) kg (P = 0.021) Table 2].
Islet B-cell function and dysfunction
Despite lower FPG levels with rosi + met (above), serum C-
peptide levels were similar in the two groups at 24 weeks, with
identical change from baseline (Table  2). Proinsulin levels,
while similar at baseline, fell only in the rosi + met group, and
were notably lower at 24 weeks, with a significantly different
change in levels from baseline compared with the placebo
group (P < 0.001, Table 2). Consistent with these data, the
proinsulin:C-peptide ratio change from baseline was also
different in the two groups (P < 0.001; Table 2).
Health perception measures
Measures of health perception suggested a greater level of
treatment satisfaction in participants who received rosi + met
compared with placebo. From baseline to week 24, the DTSQs
score increased in the rosi + met group and decreased with
placebo [difference 1.5 (0.2, 2.7) points, P = 0.024; Table 2].
The DTSQc total score, a measure of improvement in satisfac-
tion, was significantly higher in the rosi + met group than in
the placebo group at week 24 [difference 1.9 (0.4, 3.4) points,
P = 0.014; Table 2].
FIGURE 1 Time courses for daily insulin dose, HbA1c and clinic FPG for 
people with Type 2 diabetes starting insulin while continuing 
rosiglitazone + metformin ( ) or transferring to placebo ( ). Data are 
mean ± SE for ITT populations with LOCF, except for dose which is 
without LOCF. For statistical significance see Results and Table 2.
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Table 2 Changes in efficacy and health perception measures from baseline to week 24 when starting insulin and continuing or discontinuing rosiglitazone + metformin fixed-dose combination therapy
Rosiglitazone + metformin and insulin Placebo and insulin
Treatment comparison as 
difference or odds ratio
P Baseline Week 24 Baseline Week 24
Insulin dose (U/day) 21.7 ± 0.4* 33.5 ± 1.5 23.1 ± 0.4* 59.0 ± 3.0 −26.6 (−37.7, −15.5) < 0.001
HbA1c (%) 8.7 ± 0.1 6.8 ± 0.1 8.8 ± 0.1 7.5 ± 0.1 −0.7 (−0.8, −0.5) < 0.001
Clinic FPG (mmol/l) 10.9 ± 0.2 7.5 ± 0.2 10.8 ± 0.2 8.9 ± 0.2 −1.4 (−1.9, −0.9) < 0.001
Target achievers [n (%)]:
HbA1c ≤ 6.5% 74 (46) 29 (19) 4.1 (2.4, 6.9) < 0.001
HbA1c < 7.0% 113 (70) 53 (34) 5.0 (3.0, 8.1) < 0.001
Clinic FPG ≤ 6.5 mmol/l 58 (36) 25 (16) 3.0 (1.8, 5.2) < 0.001
Mean daily SMBG† (mmol/l) 10.0 ± 0.2 6.8 ± 0.1 10.0 ± 0.2 8.2 ± 0.2
Hypoglycaemia events (n) 166 130 1.1 (0.6, 2.1) NS
≥ 1 event [n (%)]† 40 (25) 43 (27)
≥ 6 events [n (%)]† 9 (5) 5 (3)
Body weight (kg) 89.6 ± 1.3 93.2 ± 1.3 91.2 ± 1.3 93.7 ± 1.3 1.1 (0.2, 2.1)  0.021
C-peptide (nmol/l)‡ 0.75 (0.58, 0.97) 0.66 (0.41, 0.89) 0.77 (0.59, 1.01) 0.70 (0.45, 0.97) −0.10 (−0.27, 0.07) vs. −0.10 (−0.25, 0.12) NS
Proinsulin (pmol/l)‡ 6.4 (3.8, 9.7) 4.8 (2.6, 10.3) 6.8 (4.3, 10.1) 6.6 (4.0, 14.2) −0.8 (−4.3, 2.5) vs. 1.0 (−1.8, 4.6) < 0.001
Proinsulin:C-peptide‡ (pmol/nmol) 8.1 (5.0, 12.7) 7.6 (4.5, 14.0) 9.1 (6.2, 13.2) 10.7 (7.6, 17.6) −0.3 (−3.7, 3.2) vs. 2.0 (−0.8, 6.6) < 0.001
DTSQs score 28.5 ± 0.6 29.2 ± 0.5 27.7 ± 0.6 27.4 ± 0.6 1.5 (0.2, 2.7)  0.024
DTSQc score — 11.5 ± 0.8 — 9.6 ± 0.7 1.9 (0.4, 3.4)  0.014
FPG, clinic/laboratory fasting plasma glucose; NS, non-significant; SMBG, self-monitored blood glucose.
Mean ± SE, n (%), median (IQ range), or treatment difference from baseline to week 24 (95% CI).
ITT population with LOCF (insulin dose without LOCF), or safety population for hypoglycaemia.
*Starting insulin dose taken as baseline.
†Observational data without statistical comparison.
‡Hormonal data are analysed non-parametrically, and given as median (25–75%ile), with change from baseline rather than treatment difference.
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Safety and tolerability
Both treatment regimens were generally well tolerated. A
similar proportion of participants had on-therapy AEs in the
two treatment groups: 60 people (38%) in the rosi + met group
and 69 people (43%) with placebo. Six people (4%) in the
rosi + met group and eight people (5%) in the placebo group
had on-therapy non-fatal serious AEs. All were reported by the
investigator as apparently unrelated to study medication. One
death occurred before treatment with study drugs, and one on
rosi + met as a result of circulatory arrest.
Twelve participants (7%) in the rosi + met group had oedema,
compared with four (3%) in the placebo group; all were
judged mild or moderate, but two cases in the rosi + met group
led to withdrawal from the study. In those participants who
developed oedema, mean weight gain was 4.0 ± 1.7 kg in the
placebo group and 5.0 ± 0.8 kg in the rosi + met group. There
were no cases of heart failure in either treatment group, but
one occurrence of angina pectoris (judged severe) on rosi + met,
associated with weight loss (−7.1 kg).
Conclusions
In this randomized controlled study, the addition of insulin to
rosi + met significantly improved glycaemic control and increased
the proportion of individuals achieving glycaemic targets when
compared with insulin alone. Importantly, these changes were
seen despite markedly lower insulin doses in the group contin-
uing on rosi + met, and with no difference in the proportion of
participants reporting hypoglycaemia during the last 12 weeks
of the study (the period for which the insulin dose was stable).
This improved blood glucose control with lower insulin doses
was reflected in improved treatment satisfaction measures,
known to primarily reflect changes in perceived control [23].
A comparison between the insulin-sparing effect of rosi + met in
this study and previous studies of OGLDs in combination with
insulin suggests rosi + met may have an additional insulin-
sparing effect over that seen with metformin plus insulin [2,3].
The increased incidence of oedema in participants continu-
ing on rosi + met compared with insulin plus placebo (7 vs. 3%)
was lower than in a previous study of insulin plus rosiglitazone
[19], although still measurable, and with no cases of heart
failure. The lower rate of oedema in this study may reflect
the gradual up titration of insulin therapy. The lower dose of
insulin required with rosi + met may also have helped, as oedema
associated with thiazolidinedione treatment is greater when
thiazolidinediones are used in combination with insulin [20].
The significantly greater mean weight gain seen with
rosi + met therapy in this study is consistent with a systematic
review reporting that weight gain with thiazolidinediones in
combination with insulin is consistently associated with
improved glycaemic control [2]. The weight difference from
the placebo group is consistent with the difference in blood
glucose control [4]. The gain of 3.7 kg in the present study was
less than the 5.3 kg previously observed when rosiglitazone
8  mg/day was used with insulin [19], suggesting that met-
formin may have a mitigating effect on the weight change, in
line with previous reports of metformin added to insulin [2,3]
and of metformin plus rosiglitazone [10,18].
Mechanistically, the lower insulin dose required in the
rosi + met group supports the rationale for improving insulin
sensitivity, as indicated by the combination of lower insulin
requirements and lower HbA1c. Reducing the insulin dose may
offer health benefits in terms of reducing the risk of hypogly-
caemia [24] and hyperinsulinaemia [25], along with other
putative benefits such as reducing the hunger stimulus and the
frequency of injections, together with some cost offset. The
lack of change in fasting serum C-peptide despite lower
glucose levels implies improved islet B-cell function, but
the present study cannot discriminate whether this is a direct
effect or is secondary to the improvement in blood glucose
and metabolic control. However, the fall in proinsulin and proin-
sulin:C-peptide ratio, not seen with the smaller improve-
ment of glucose control in the placebo group, implies
improved processing of proinsulin to insulin with continua-
tion of rosi + met when starting insulin. More stable blood
glucose control has been known for decades to be related to
preservation of endogenous insulin secretion, and this may be
another reason why the insulin sensitizers did not result in
increased hypoglycaemia in this study. It is yet to be determined
whether these changes have long-term implications for preser-
vation of endogenous insulin secretion.
This study provides further support for current guidelines
that recommend continuation of OGLD therapy while insulin
is introduced [7,8]. This study is also in agreement with recent
studies suggesting that titration of insulin to achieve glycaemic
targets allows improved glycaemic control while minimizing
the risk of hypoglycaemia [26–28]. In the current study,
almost half of the group randomized to rosi + met was able to
achieve HbA1c ≤ 6.5%, the target in the latest evidence-based
guidelines such as those of the International Diabetes Federa-
tion [8,29,30], despite starting levels (mean 8.7%) well above
usual recommendations for starting insulin. In contrast, less
than one-third of those randomized to insulin plus placebo
achieved this target.
There are several limitations that must be considered when
making comparisons with other studies. The regimen used for
insulin dose adjustment was less aggressive than in some recent
studies [4,19], which may account for the higher HbA1c values
obtained with insulin monotherapy here compared with studies
that have used alternative insulin regimens [4]. In addition,
it is important to note that, while the aim of this study was to
examine continuation or discontinuation of rosi + met when
initiating insulin, current guidelines advise the continuation of
metformin when transferring patients to insulin [7,8].
The present results appear to be generally applicable as
a result of the inclusion of a typical Type 2 diabetes starter
population in line with treatment recommendations, although
excluding those with a history of cardiac failure [7,8]. A future
investigation could consider a comparator group treated with
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insulin added to metformin monotherapy; meanwhile, how-
ever, the results appear better than those achieved in other
recent studies of insulin initiation in which OGLDs were
continued [26,28,31], although inter-study comparisons must
be made with caution.
In conclusion, the addition of insulin to rosi + met as a fixed-
dose combination proved effective, well tolerated, and enabled
more individuals to reach glycaemic targets, with a lower insulin
dose requirement than for insulin monotherapy.
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